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US-China Health Exchange and Collaboration in a Post-COVID-19 Era 
 
Summary: 
With the backdrop of a continuing pandemic, we encourage a strong US-China collaboration on 
health and medicine,  as a crucial element of the global fight against COVID-19. We review the 
history of health collaboration and exchanges between the two countries' public and private 
sectors, including the long-lasting collaboration between governmental public health agencies of 
the two countries. Academic and scientific exchanges should be reinvigorated, and the increasing 
valuable role of nonprofit foundations acknowledged. The shared interests of the two countries 
and the magnitude of the pandemic necessitate both countries to collaborate and cooperate. We 
provide recommendations to the two governments and the global health community to control 
the current pandemic and prepare for future threats. 





US-China Health Exchange and Collaboration in a Post-COVID-19 Era 
For the last few years, trade, tariff, other economic and security issues have cast a chill on US-
China relations. These have been exacerbated by events related to the COVID-19 pandemic, 
including who knew what/when, issues of transparency and data sharing, and public disputes 
between the two countries. In this viewpoint, we argue for the viability of the US-China health 
exchange and collaboration with a historical perspective on what had been achieved in this area, 
point to the urgency of such exchange and collaboration after turbulent years rife with distrust 
and disagreements, and outline key areas that are promising to benefit both countries. 
History on US-China Health Collaboration  
The US-China relationship in health and medicine has fared better than the political interface. 
Since the days of President Richard Nixon’s visit, scientific exchange and partnering efforts have 
flourished between the US and China. In early 1980, the corresponding author (Dr. Koplan) had 
the good fortune to be a member of the first official US government team of health leaders, to 
visit China promoting collaboration in the fields of Public Health and Health Services 
Research.1,2 He represented the US Centers for Disease Control and Prevention (CDC) while 
other team members included directors of major institutes of the National Institutes of Health 
(NIH) and Dr. Julius Richmond, the then US Assistant Secretary for Health. In partnership with 
Chinese academicians and government leaders, a long-term taskforce was formed, co-chaired by 
Dr. Koplan and Professor Yang Ming-Ding of Shanghai Medical University. 
This promptly led to substantive collaboration – a research agenda and a supplementary issue of 
the American Journal of Public Health on public health in China with each paper co-authored by 
Chinese and US scholars.3  Further exchanges followed. Over the next several decades, ties 
flourished between the US and Chinese health research institutions. Hundreds of MOUs between 
educational institutions, health science centers, and hospitals have been established along with 
many substantive and sustained relationships.4 
Box 1 lists a small portion of the many accomplishments in biomedical research, medical 
education, public health, and global health between government agencies, academic institutions, 
nonprofit organizations, and private sectors.  
Box 1: Accomplishments of Past US-China Health and Medicine Collaborations 
Sector Collaboration Field 
Government  Public Health System: The US CDC has worked together 
closely with Chinese public health leadership for over 35 years 
to develop an effective and responsive public health system in 
China and achieved improved institutions at the national, 
provincial, and municipal levels.2,5 
Public 
health 
Outbreak Investigation and Reporting: The China CDC 
Weekly, a scientific journal modeled after the US CDC 
Morbidity and Mortality Weekly Report (MMWR), is a 
collaborative effort between China and US CDCs. The journal 





The US-China Global Disease Detection Cooperative 
Agreements: From 2004 to 2014, the Chinese National 
Influenza Center (CNIC) and the US CDC developed 
cooperative agreements to build capacity in influenza 
surveillance in China.5 The initiative lead to a network of 411 
laboratories and 556 sentinel hospitals (as of 2009) and a 
Weekly Influenza Reports, in both Chinese and English, shared 
among key stakeholders and published on the CNIC website.  
Public 
Health 
The African CDC: The African CDC has benefited from US-




Combating Ebola in West Africa: US and China collaborated 
successfully in laboratory capacity, logistics, and drug 
development to combat Ebola.8  
Global 
health 
The China-US Collaborative Project for Neural Tube Defect 
Prevention: A partnership between US CDC and Chinese 
institutions to generate high-quality evidence for folic acid 
fortification, leading to policy changes in the US.9  
Biomedical 
science 
Human Genome Project: A collaborative efforts between 20 
scientific centers in six countries, China, France, Germany, 




Academia The China Tobacco Control Partnership: Strong and 
effective tobacco control programs of the Partnership, in 
collaboration with Emory Global Health Institute, the Gates 
Foundation, and a China-based non-governmental organization, 
The ThinkTank Research Center for Health Development, in 22 
cities in China, have resulted in marked reductions in smoking 
in public places.11 
Public 
health 
Yale University: Dating back to 1835 when Yale graduate Peter 
Parker opened the first Western-style hospital in China, Yale 
University has maintained a collaborative relationship with 
Chinese institutions, particularly the Central South University, 




Harvard China Health Partnership (HCHP): HCHP provides 
a platform for faculty across Harvard University to advance 







China Medical Board (CMB): Founded in 1914 with 
endowments from the Rockefeller Foundation, CMB strives to 
advance health, equity, and the quality of care in China and 
Southeast Asia. Key focuses of CMB include health policy and 





Resolve to Save Lives: An initiative founded by a former 
director of the US CDC, Dr. Thomas Frieden, Resolve to Save 






institutions to prevent deaths from cardiovascular disease 
through hypertension control and sodium reduction policies.15   
Gates Foundation: Bill and Melinda Gates Foundation has an 
office in Beijing, working with Chinese partners to develop 
innovative low-cost vaccines and vaccine refrigeration 
equipment for low-income settings, low-cost interventions to 




Examples abound of the productive and reciprocal health and medicine collaboration between 
the two governments. The China-US Collaborative Project for Neural Tube Defect Prevention, a 
partnership between the US CDC and Chinese institutions during the 1990s, produced landmark 
findings on the efficacy of folic acid and contributed to the evidence base for mandatory folic 
acid fortification policies in the US.9,17 In January 2002, the Chinese Academy of Preventive 
Medicine was reorganized into the Chinese Center for Disease Control and Prevention (China 
CDC), which was established as China’s premier public health agency. The US CDC and Dr. 
Koplan, who was the director of the US CDC at the time, worked closely with the newly founded 
China CDC and its founding director, Dr. Liming Li. The two sister agencies signed a 
Memorandum of Cooperation and until recently held annual director-level meetings to report on 
progress and exchange views on global health and collaborations. The US CDC helped China 
establish programs, including the China Field Epidemiology Training Program (CFETP), the 
Tuberculosis Prevention and Control Cooperation Project, among others. These collaborations 
have played a critical role in China’s responses to emerging infectious diseases, such as Severe 
Acute Respiratory Syndrome (SARS), avian influenza, and COVID-19, and are crucial to US 
global health security. The national scientific funding agencies, the US NIH and the National 
Natural Science Foundation, China (NSFC), have partnered to encourage collaborative 
biomedical research even as the bilateral relationship has soured.18      
In academia, since the Carter Administration opened the door for US-China student exchange, 
Chinese students at every educational level, estimated at over 350,000 in recent years, are 
studying in the US.19,20  The number of Chinese students who received a doctoral degree in the 
United States reached 6,182 in 2018.20 Many of those with biomedical training have returned to 
China, while some of those who came to the US earlier have taken leadership roles, such as 
department chairs and deanships in both the US and China. Misuse of data, challenges to 
intellectual property, and frayed partner relationships have occurred.21 But these unfortunate 
events have been few in comparison to the tens of thousands of trainees, faculty exchanges, and 
successful research collaborations in biomedical and public health. Yale University and Harvard 
University are two of the many US educational institutions that have long-lasting collaborations 
with Chinese counterparts on topics related to health and medicine.12,13   
Nonprofit foundations have played an instrumental role in US-China health exchange and 
collaboration. The China Medical Board (CMB), for over 100 years, has collaborated with 
medical universities and schools of public health and nursing in China to train healthcare 
professionals, provide incentives for doctors to stay in needy areas, and develop capacities in 
global health and health policy and system sciences (HPSS) in China.14,22 Bill and Melinda Gates 
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Foundation has funded initiatives in China directly and through other agencies, including Emory 
Global Health Institute and Resolve to Save Lives,11,15,16 to promote health in China and to 
harness the manufacturing capability in China to develop innovative and low-cost means to 
benefit people in need elsewhere.   
To benefit the health of people in both countries, we need to maintain and support our 
productive, mutually beneficial medical and scientific exchanges and collaborations in every 
sector of the two societies. 
Challenges and Opportunities in US-China Health Collaboration 
Challenges to the US-China health collaboration exist, including those deeply rooted political 
and economic differences, acute stresses related to the pandemic, and more targeted global 
trends, including mental health issues, NCD, aging, urbanization, climate change that are of joint 
concerns. The political and economic differences need to be acknowledged and may require a 
long-term solution involving continuing dialogues. The other two types of challenges lend 
themselves to be addressed given common concerns and value of collaboration. 
In recent years, even before the pandemic, steps have been taken by both countries that hinder 
bonds of scientific inquiry, friendship, and productivity.2,23 The US CDC China Office has had a 
significant reduction of its staff, compromising collaborative efforts.2 The past several years have 
been stressful for Chinese scholars in the US, particularly those who have close collaborations 
with Chinese institutions.23 The intensity of these stresses has increased along with those 
emanating from the pandemic. The conflict has been initiated and has intensified more at the 
higher political levels than at the scientific/technical levels.  
As an unresolved pandemic continues to threaten everyone, everywhere, travel will be 
compromised for the near future. There will be less face-to-face collaboration, even with 
masking as the norm. But collaboration will continue through virtual means, with the eventual 
return to common practice of in-person travel and face-to-face meetings. Anticipation of one or 
more effective and safe vaccines may be promising but not assured. Even excellent vaccines may 
be introduced to a population that is skeptical, untrusting, and wary, with vaccine hesitancy a 
challenge. Strong US and Chinese collaboration in vaccine development and distribution would 
benefit both countries and the world.  
There are also many inherent long-term societal and health challenges that confront both nations 
will only be greater in years to come, alluding to collaborative opportunities in health and 
medicine. These include: urban health as China experiences dramatic urban growth and develops 
its megacities; aging populations in both countries with expanded demands for medical and 
social services for older adults; environmental degradation, climate change, clean water, air, and 
soil; energy needs and approaches; policy and economic issues in which health has a major 
stake; non-communicable diseases and their risk factors, including tobacco use/smoking, 
diet/overnutrition, salt intake, fat intake, physical activity, diabetes, heart disease and stroke, 
mental health and substance abuse, arthritis and mobility and injuries.   
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Besides the ongoing pandemic, long-running global health challenges include fragile health 
systems in the low-and-middle-income countries that can be overwhelmed by an emerging 
infectious disease or a pandemic of chronic diseases. The US and China may complement each 
other in their global health aid and engagement despite differences in objectives, approaches, and 
where they succeed and fail. The US has extensive experience in evaluating health aid programs 
and may offer lessons learned. China may operate with more security and efficiency in certain 
geopolitical settings that are out of reach for the US. China may also complement the American 
prowess in technology and management with its strengths in manpower and logistics, as the US-
China collaboration in combatting Ebola has demonstrated. The US also has a much larger 
global health workforce and more global health academic programs, supporting the scale of 
operation of the US global health engagement. The Chinese global health programs are limited in 
number and scale. Much may be shared through collaboration and exchange between the global 
health communities in the US and China. Global health science and knowledge will be enriched 
from a bi-directional exchange.24   
What will the post-pandemic US-China health and medicine collaboration be like? The 
immediate future will be challenging. However, we have so much to learn from and offer to each 
other that our biomedical and public health ties must be maintained and strengthened. It makes 
sense for US and Chinese scientists to work together on elements of the pandemic response and 
best practices for future pandemics.   
Recommendations for US-China Health Collaboration in Post-COVID-19 Era 
Looking forward, amidst the pandemic, what are the prospects for the very productive and 
mutually valuable US-China health exchange and collaboration?  
The health and medicine collaborations between the US and China have been fruitful, as we have 
shown earlier. We refer to the US and China, but in reality, it is global – every nation on the 
planet is threatened as long as the virus circulates. Although elimination of transmission in one 
country may be excellent as far as that nation goes, it must prepare for the re-introduction of the 
virus and its rapid propagation. There is great value in our addressing the pandemic in 
partnerships, collegially, sharing information, being transparent, improving communications in 
accuracy and timeliness. The collaboration must be kept alive and nurtured to support our 
common interests and to address health challenges and threats. 
These are perilous times threatened by a very dangerous virus and heightened political tensions. 
We hope new leadership in the US can help resolve our political and economic differences. 
There are many areas of real or potential conflict. However, health and medicine are areas where 
we have shown we can work together productively for mutual benefits – because we live in an 
interconnected world.25 Collaborations and exchanges will be more important than ever. We 
need to learn together and appreciate our similarities and differences. We are intellectually 
enhanced and socially challenged by both. We all benefit from working with and enjoying each 
other’s energy and accomplishments in research and application of our scientific findings. 
We offer three immediate recommendations:  
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1. To weather through the current pandemic and to prepare for future outbreaks and pandemics, 
we need to restore partnership and collaboration on health and medicine between the US and 
Chinese government agencies that has been hampered by politics;26-28 The collaboration could be 
between the CDCs,29 between the FDA and the China Drug Administration, between USAID and 
CIDCA,30 and between the China Academy of Medical Sciences and the NIH. We welcome the 
announcement from the Biden Administration that the US will not withdraw from the WHO and 
will participate in the COVID-19 Vaccine Global Access (COVAX) Facility, providing an 
opportunity where the US may collaborate with the WHO and China to provide funds for 
countries that lack the financial resources.31 The two countries may go beyond the COVAX 
initiative to increase access to COVID-19 vaccines in low-and-middle-income countries as called 
upon by a recent Lancet editorial.32 With its experience and strengths in mass testing, China may 
team up with the US to assist African countries in testing and screening of COVID-19 cases to 
contain the pandemic. The US and China should work with WHO and other nations to expand 
the “Yellow Card vaccination record” to address needs generated by the COVID-19 pandemic. 
2. To facilitate the collaboration and exchange between the academic and scientific communities 
that has been hindered by both political considerations and the pandemic. Scholarly exchanges 
continue to exist amid the tensions and the pandemic but the momentum may be dampened if the 
set course continues.33,34 Collaboration and exchange in health and medicine between academic 
institutions should be encouraged rather than held back. Previous missteps, such as the 
discontinuation of the Fulbright Program in China, should be reversed. Both sides should invest 
in earnest efforts to improve bilateral exchanges in science and cultural perspectives.  
3. The business case for US-China collaboration on health and medicine is evident. US and 
China may collaborate in investing in innovations for health, expanding market access for 
pharmaceuticals, regulatory control of synthetic opioids, with benefits to both US and China.27 
There are ample opportunities for the private sector, including businesses and nonprofit 
organizations, to work with the governments in both countries to improve US-China 
collaboration on health and medicine.  
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